Victoria Auerbuch, published name

View our publications on PubMed here.
2021
  • Developing Cyclic Peptomers as Broad-Spectrum Type III Secretion System Inhibitors in Gram-Negative Bacteria.
    Lam HN, Lau T, Lentz A, Sherry J, Cabrera-Cortez A, Hug K, Lalljie A, Engel J, Lokey RS, Auerbuch V.
    Antimicrob Agents Chemother. 2021 Jun. doi: 10.1128/AAC.01690-20.
  • Genome Scale Analysis Reveals IscR Directly and Indirectly Regulates Virulence Factor Genes in Pathogenic Yersinia.
    Balderas D, Mettert E, Lam HN, Banerjee R, Gverzdys T, Alvarez P, Saarunya G, Tanner N, Zoubedi A, Wei Y, Kiley PJ, Auerbuch V.
    mBio. 2021 Jun. doi: 10.1128/mBio.00633-21.
2020
  • The Yersinia Type III Secretion System as a Tool for Studying Cytosolic Innate Immune Surveillance.
    Schubert KA, Xu Y, Shao F, Auerbuch V.
    Annu Rev Microbiol. 2020 Sep. doi: 10.1146/annurev-micro-020518-120221.
2019
  • Iron availability and oxygen tension regulate the Yersinia Ysc type III secretion system to enable disseminated infection.
    Hooker-Romero D, Mettert E, Schwiesow L, Balderas D, Alvarez PA, Kicin A, Gonzalez AL, Plano GV, Kiley PJ, Auerbuch V.
    PLoS Pathog. 2019 Dec. doi: 10.1371/journal.ppat.1008001.
  • Mouse Models of Yersiniosis.
    Hooker-Romero D, Schwiesow L, Wei Y, Auerbuch V.
    Methods Mol Biol. 2019. doi: 10.1007/978-1-4939-9541-7_4.
  • Editorial: The Pathogenic Yersiniae-Advances in the Understanding of Physiology and Virulence, Second Edition.
    Francis MS, Auerbuch V.
    Front Cell Infect Microbiol. 2019 Apr. doi: 10.3389/fcimb.2019.00119.
  • Complete Genome Assembly of Yersinia pseudotuberculosis IP2666pIB1.
    Zoubeidi A, Schwiesow L, Auerbuch V, Lam HN.
    Microbiol Resour Announc. 2019 Feb. doi: 10.1128/MRA.01592-18.
2018
  • An Experimental Pipeline for Initial Characterization of Bacterial Type III Secretion System Inhibitor Mode of Action Using Enteropathogenic Yersinia.
    Morgan JM, Lam HN, Delgado J, Luu J, Mohammadi S, Isberg RR, Wang H, Auerbuch V.
    Front Cell Infect Microbiol. 2018 Nov. doi: 10.3389/fcimb.2018.00404.
  • Control of hmu Heme Uptake Genes in Yersinia pseudotuberculosis in Response to Iron Sources.
    Schwiesow L, Mettert E, Wei Y, Miller HK, Herrera NG, Balderas D, Kiley PJ, Auerbuch V.
    Front Cell Infect Microbiol. 2018 Feb. doi: 10.3389/fcimb.2018.00047.
2017
  • Investigation of the Physical and Bioactive Properties of Bromo- and Iodo-Containing Sponge-Derived Compounds Possessing an Oxyphenylethanamine Core.
    McCauley EP, Lam H, Lorig-Roach N, Luu J, Lloyd C, Tenney K, Pietraszkiewicz H, Diaz C, Valeriote FA, Auerbuch V, Crews P.
    J Nat Prod. 2017 Dec. doi: 10.1021/acs.jnatprod.7b00694.
  • Synthetic Cyclic Peptomers as Type III Secretion System Inhibitors.
    Lam H, Schwochert J, Lao Y, Lau T, Lloyd C, Luu J, Kooner O, Morgan J, Lokey S, Auerbuch V.
    Antimicrob Agents Chemother. 2017 Aug. doi: 10.1128/AAC.00060-17.
  • Piericidin A1 Blocks Yersinia Ysc Type III Secretion System Needle Assembly.
    Morgan JM, Duncan MC, Johnson KS, Diepold A, Lam H, Dupzyk AJ, Martin LR, Wong WR, Armitage JP, Linington RG, Auerbuch V.
    mSphere. 2017 Feb. doi: 10.1128/mSphere.00030-17.
  • Bacterial internalization is required to trigger NIK-dependent NF-κB activation in response to the bacterial type three secretion system.
    Duncan MC, Herrera NG, Johnson KS, Engel JN, Auerbuch V.
    PLoS One. 2017 Feb. doi: 10.1371/journal.pone.0171406.
2016
  • The Type III Secretion System Cleans up Its Act(in).
    Auerbuch V.
    Cell Host Microbe. 2016 Sep. doi: 10.1016/j.chom.2016.08.012.
  • Hereditary Hemochromatosis Predisposes Mice to Yersinia pseudotuberculosis Infection Even in the Absence of the Type III Secretion System.
    Miller HK, Schwiesow L, Au-Yeung W, Auerbuch V.
    Front Cell Infect Microbiol. 2016 Jun. doi: 10.3389/fcimb.2016.00069.
  • Erratum for Duncan et al., An NF-κB-Based High-Throughput Screen Identifies Piericidins as Inhibitors of the Yersinia pseudotuberculosis Type III Secretion System.
    Duncan MC, Wong WR, Dupzyk AJ, Bray WM, Linington RG, Auerbuch V.
    Antimicrob Agents Chemother. 2016 Jun. doi: 10.1128/AAC.00973-16.
2015
  • Yersinia Type III Secretion System Master Regulator LcrF.
    Schwiesow L, Lam H, Dersch P, Auerbuch V.
    J Bacteriol. 2015 Dec. doi: 10.1128/JB.00686-15.
  • Bacterial iron-sulfur cluster sensors in mammalian pathogens.
    Miller HK, Auerbuch V.
    Metallomics. 2015 Jun. doi: 10.1039/c5mt00012b.
  • Yersinia pseudotuberculosis YopD mutants that genetically separate effector protein translocation from host membrane disruption.
    Adams W, Morgan J, Kwuan L, Auerbuch V.
    Mol Microbiol. 2015 May. doi: 10.1111/mmi.12970.
2014
  • IscR is essential for yersinia pseudotuberculosis type III secretion and virulence.
    Miller HK, Kwuan L, Schwiesow L, Bernick DL, Mettert E, Ramirez HA, Ragle JM, Chan PP, Kiley PJ, Lowe TM, Auerbuch V.
    PLoS Pathog. 2014 Jun. doi: 10.1371/journal.ppat.1004194.
  • An NF-κB-based high-throughput screen identifies piericidins as inhibitors of the Yersinia pseudotuberculosis type III secretion system.
    Duncan MC, Wong WR, Dupzyk AJ, Bray WM, Linington RG, Auerbuch V.
    Antimicrob Agents Chemother. 2014. doi: 10.1128/AAC.02025-13.
2013
  • Impact of host membrane pore formation by the Yersinia pseudotuberculosis type III secretion system on the macrophage innate immune response.
    Kwuan L, Adams W, Auerbuch V.
    Infect Immun. 2013 Mar. doi: 10.1128/IAI.01014-12.
2012
  • Chemical inhibitors of the type three secretion system: disarming bacterial pathogens.
    Duncan MC, Linington RG, Auerbuch V.
    Antimicrob Agents Chemother. 2012 Nov. doi: 10.1128/AAC.00975-12.
2009 and earlier
  • Innate immune recognition of Yersinia pseudotuberculosis type III secretion.
    Auerbuch V, Golenbock DT, Isberg RR.
    PLoS Pathog. 2009 Dec. doi: 10.1371/journal.ppat.1000686.
  • Growth of Yersinia pseudotuberculosis in mice occurs independently of Toll-like receptor 2 expression and induction of interleukin-10.
    Auerbuch V, Isberg RR.
    Infect Immun. 2007 Jul;75(7):3561-70.
  • Bacterial ligands generated in a phagosome are targets of the cytosolic innate immune system.
    Herskovits AA, Auerbuch V, Portnoy DA.
    PLoS Pathog. 2007 Mar;3(3):e51.
  • Mice lacking the type I interferon receptor are resistant to Listeria monocytogenes.
    Auerbuch V, Brockstedt DG, Meyer-Morse N, O’Riordan M, Portnoy DA.
    J Exp Med. 2004 Aug 16;200(4):527-33.
  • Ena/VASP proteins contribute to Listeria monocytogenes pathogenesis by controlling temporal and spatial persistence of bacterial actin-based motility.
    Auerbuch V, Loureiro JJ, Gertler FB, Theriot JA, Portnoy DA.
    Mol Microbiol. 2003 Sep;49(5):1361-75.
  • The cell biology of Listeria monocytogenes infection: the intersection of bacterial pathogenesis and cell-mediated immunity.
    Portnoy DA, Auerbuch V, Glomski IJ.
    J Cell Biol. 2002 Aug 5;158(3):409-14.
  • Microbial pathogenesis and the eukaryotic cytoskeleton at the American Society for Cell Biology annual meeting.
    Auerbuch V, Portnoy DA.
    Cell Microbiol. 2002 Mar;4(3):187-90.
  • Pivotal role of VASP in Arp2/3 complex-mediated actin nucleation, actin branch-formation, and Listeria monocytogenes motility.
    Skoble J, Auerbuch V, Goley ED, Welch MD, Portnoy DA.
    J Cell Biol. 2001 Oct 1;155(1):89-100.
  • Development of a competitive index assay to evaluate the virulence of Listeria monocytogenes actA mutants during primary and secondary infection of mice.
    Auerbuch V, Lenz LL, Portnoy DA.
    Infect Immun. 2001 Sep;69(9):5953-7.
  • Analysis of genes encoding an alternative nitrogenase in the archaeon Methanosarcina barkeri 227.
    Chien YT, Auerbuch V, Brabban AD, Zinder SH.
    J Bacteriol. 2000 Jun;182(11):3247-53.
  • Stability of the Listeria monocytogenes ActA protein in mammalian cells is regulated by the N-end rule pathway.
    Moors MA, Auerbuch V, Portnoy DA.
    Cell Microbiol. 1999 Nov;1(3):249-57.